VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The safety and efficacy of tagraxofusp for the treatment of BPDCN

Marco Herling, MD, University of Leipzig, Leipzig, Germany shares some insights into a retrospective analysis investigating the safety and efficacy of tagraxofusp for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Herling first highlights the importance of increasing awareness and improving treatment options for patients with BPDCN and also discusses the promising results observed with the use of tagraxofusp. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter